Journal
PHARMACEUTICS
Volume 14, Issue 5, Pages -Publisher
MDPI
DOI: 10.3390/pharmaceutics14050959
Keywords
polymeric micelles; Soluplus (R); rifampicin; curcumin; tuberculosis; inhalable nanoformulation; active drug targeting; Mycobacterium tuberculosis
Categories
Funding
- Universidad de Buenos Aires (Grant UBACyT) [20020170100362BA]
- UBA
- CONICET, Argentina
- Universidad de Buenos Aires (Grant PIDAE 2018) [SP28-FFYB-CHIA]
- CONICET
Ask authors/readers for more resources
Tuberculosis, the second deadliest infectious disease in 2020, can potentially be treated with inhaled nanocarriers for active targeting in the lungs.
Among respiratory infections, tuberculosis was the second deadliest infectious disease in 2020 behind COVID-19. Inhalable nanocarriers offer the possibility of actively targeting antituberculosis drugs to the lungs, especially to alveolar macrophages (cellular reservoirs of the Mycobacterium tuberculosis). Our strategy was based on the development of a mannose-decorated micellar nanoformulation based in Soluplus (R) to co-encapsulate rifampicin and curcumin. The former is one of the most effective anti-tuberculosis first-line drugs, while curcumin has demonstrated potential anti-mycobacterial properties. Mannose-coated rifampicin (10 mg/mL)-curcumin (5 mg/mL)-loaded polymeric micelles (10% w/v) demonstrated excellent colloidal properties with micellar size similar to 108 +/- 1 nm after freeze-drying, and they remain stable under dilution in simulated interstitial lung fluid. Drug-loaded polymeric micelles were suitable for drug delivery to the deep lung with lung accumulation, according to the in vitro nebulization studies and the in vivo biodistribution assays of radiolabeled (99mTc) polymeric micelles, respectively. Hence, the nanoformulation did not exhibit hemolytic potential. Interestingly, the addition of mannose significantly improved (5.2-fold) the microbicidal efficacy against Mycobacterium tuberculosis H37Rv of the drug-co-loaded systems in comparison with their counterpart mannose-free polymeric micelles. Thus, this novel inhaled nanoformulation has demonstrated its potential for active drug delivery in pulmonary tuberculosis therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available